8:55 - 5:10 EDT | 5:55 - 2:10 PDT

8:30 am Virtual Coffee Networking

8:55 am Chair’s Opening Remarks

9:00 am Revisiting Autologous NK Cell-based Immunotherapy for Human Cance


• Allogeneic NK cell-based immunotherapies have proven successful in several
settings of human hematological malignancies. Furthermore, they provide great
potential for “off-the-shelf” development
• In contrast, comparably few recent approaches have been made towards
exploring the potential of autologous NK cells
• Here, we revisit autologous NK cell-based treatment strategies, and demonstrate
the applicability multiple dose infusions of ex vivo activated and expanded
autologous NK cells in maintenance treatment settings

9:30 am Strategies to Generate Potent NK Cells as a Universal Source


  • Outlining strategies to genetically modify NK cells with minimal manipulation in
    an effective manner
  • A relatively agnostic comparison of strategies to expand autologous and
    allogeneic NK cell products
  • Highlighting strategies to decrease the lag time of initial cultivation period for NK
    cell expansion leading to faster time to dose
  • Covering transient gene modification strategies and potential application areas
  • Revealing results of a clinical trial using autologous NK cells in patients with
    multiple myeloma

10:00 am Closed-System Manufacturing: Culture, Harvest, and Cryopreservation

  • Alaina Schlinker Senior Manager, Cell Therapy Application Support, Fresenius Kabi


  • Demonstrated, simplified culture using the G-Rex System
  • Efficient harvest, wash and concentrate using the LOVO Cell Processing System
  • Formulation and aliquoting in preparation for cryopreservation using a new, in-development, small volume cell processing system

10:10 am Creating New Treatment Options for Patients Through the Activation & Redirection of Innate Immune Cells

  • Joachim Koch Head Translational Reseach & Innovaiton, Affimed GmbH


  • Highlighting how tumor immune evasion strategies lead to disarming of innate immunity by the tumor
  • Demonstrating that through the activation and redirection of innate immune cells, innate cell engagers (ICEs) can restore immunosurveillance providing clinical benefit in heavily pre-treated patients suffering from hematological malignancies
  • High NK cell counts prior and during treatment with ICEs is a common feature of responsive patients
  • Outlining that the combination of immune cell engagers with adoptive NK cell transfer holds promise to provide additional benefit in a broad set of patients including hematological and solid malignancies

10:40 am Next Generation of Genetically Engineered NK Cells for Adoptive Immunotherapy


• Treating solid tumors with off-the-shelf engineered aNK cell lines targeting PD-L1 immune checkpoint
• Improving activity against the tumor microenvironment through targeting of MDSCs and resistance to hypoxic conditions
• Targeting COVID-19 with off-the-shelf CD16-expressing NK cells and convalescent plasma

11:10 am Virtual Speed Networking & Morning Break

Research & Development

Manufacturing & Commercialization

Hearing Novel Approaches to Enhancing Cell Therapy Efficacy in Solid Tumors

Exploring Novel Manufacturing Approaches for Allogeneic Cell Therapies

11.40 Addressing NK Cell Dysfunction in the Solid Tumor Microenvironment

• Deficiencies in intracellular cytokine signaling within TME can impede NK function
• NK cell checkpoint ligands are abundant within TME and impede NK function
• Engineering approaches to counter these inhibitor mechanisms will be presented

Robin Parihar, Assistant Professor, Baylor College of Medicine

11:40 Vγ1+ γδ T Cells – Allogenic "Off-the-shelf" T Cell Therapies for Solid Tumors & Hematologic Malignancies

• The role of Vγ1+ γδ T cells in cancer immune surveillance
• Vγ1+ γδ T cells from tissues or blood – Why bother?
• Exploring the unique properties of γδ T cells to build an allogeneic cell therapy platform

Alice Brown, VP of Research, Gamma Delta Therapeutics

12.10 Leveraging NK Cells in IO Combinations for Treatment of Solid Tumors

• Highlighting current evidence supporting combinatorial NK cell/IO approaches
• Covering NK cell/checkpoint combinations
• Discussing NK cell/therapeutic antibodies combinations
• Exploring applications of NK cells with oncolytic viruses

Alicja Copik, Research Assistant Professor, UCF

12.10 Manufacture of Human iPS-NK Cells in a Scalable 3D Sphere System

• Unlimited Source of human Pluripotent Stem Cells

• New manufacture platform of NK cells utilizing Human Pluripotent Stem Cells as unlimited source

• Feeder-free 3D suspension culture ideal for single-use-bioreactor

• High purity, functionality, and unlimited possibility for NK cytotoxicity enhancement

Allen Feng, CSO, HebeCell Corp

12.40 CTL & NK Cells are Required for Successful Immunotherapy to Cure Human Solid Tumor in a Novel Syngeneic Patient Derived Xenograft Model of Lung Cancer

• Human-donor-matched PDX - Immune System models for the in vivo testing of combination immunotherapies to solid tumor are achievable, harbor human immune cells in their tissues post-transplant, and human immune cells in PDX mice resemble exhausted tumor TILs
• Revealing that combination immunotherapy shrinks tumor in syngeneic PDX mice, and prevent tumor escape from checkpoint blockade therapy
• Highlighting that NK and CTL are equally required for successful combination immunotherapy of PDX mice

Silke Paust, Associate Professor, The Scripps Research Institute 

12.40 The Advantages of Cord Blood Donor Cells in Commercial-Scale Manufacturing of a True Off-theShelf Allogeneic NK Cell Therapy

• Description of a manufacturing process utilizing the advantages of cord blood donors coupled to the scale of a bioreactor expansion method in a commercial facility
• Exploring the broad clinical potential of a highly active, highly scalable, non-genetically modified NK cell in combination with therapeutic monoclonal antibodies
• Engineering when required: NK-specific CAR constructs and CRISPR editing to enhance NK therapeutic effect

Peter Flynn, CTO, Artiva Biotherapeutics Inc.

1:10 pm Virtual Demo & Lunch Break

Examining Next Generation NK Cell Products & Looking to the Future

2:10 pm Century Therapeutics iPSC-derived Allogeneic Cell Therapies for Cancer


  • Century iPSC-derived iNK cell platform; harnessing the power of induced
    pluripotent stem cells to develop novel allogeneic NK cell therapies for cancer
  • iPSC precise engineering to enable the design of allogeneic NK cells that can
    persist and safely and effectively mediate anti-tumor immunity
  • CAR design strategies that address disease-specific challenges
  • Making highly pure clinical candidate products derived from single iPSC cells

2:40 pm Development of Gene Edited iPSC CAR-NK Cell Therapy & Opportunities for Rational Design

  • Wei Li CSO, Cytovia Therapeutics


  • Clinical promise of CAR NK cell therapy: advantages over CAR-Ts and other T-Cell therapies
  • CAR NKs and multi-specific NK engagers: competitors or complementary approaches to harness the power of NK cells
  • Allogeneic CAR NK cells: are IPSCs the new best standard?
  • Gene editing and rational design of CAR NKs
  • Targeting solid tumors with CAR NKs

3:10 pm NK Cells in Drug Development 2020: Current Concepts & Case Studies

  • Amy Sharma Project Lead Scientist, Development , Genentech Inc.


  • Discussion of points to consider when assessing NK cell function in the drug development process (preclinical species selection, translation to humans, regulatory aspects, health authority interactions)
  • Defining the evidence associating NK cell dysfunction with infection and cancer for patient risk assessment
  • Consideration of emerging NK cell biology, including the impact of immunogenetics on NK cell education and function as it relates to therapeutic outcomes

3:40 pm Final Round of Virtual Speed Networking

4:10 pm Maximizing the Potential of NK Cells for Therapeutic Application


  • Discussing challenges in the expansion and engineering of NK cells
  • Genetic manipulation of NK cells to enhance tumor targeting and overcome tumor
  • Highlighting the potential of combining NK and T cells for therapeutic synergy

4:40 pm Pre-Emptive Natural Killer Donor Lymphocyte Infusion After PostTransplant Cyclophosphamide GVHD Prophylaxis Without Use of Mycophenolate: Clinical Trial Update

  • Noah Merin Professor, Cedars-Sinai Medical Centre


  • Immunology of Hematopoietic Stem Cell Transplantation – Focus on Natural Killer Immune Reconstitution
  • Covering HLA and KIR Typing, T Cell Reconstitution, NK Reconstitution, Graftversus-host and Graft versus-malignancy
  • Updated Clinical Trial Testing Augmentation of NK Recovery

5:10 pm End of Innate Killer Summit 2020